Device Trial Radar · NCT05526560
Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
504
Actual
Start
Jan 11, 2023
Primary completion
Jan 2028
Study completion Dec 2035
Sponsor
- Lead sponsor
- Edwards LifesciencesPublic (EW)
- Sponsor type
- Industry
- First posted
- Sep 2, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.
Conditions
- Mitral Stenosis
- Mitral Valve Insufficiency
Interventions
MITRIS RESILIA Mitral Valve, Model 11400MDevice
Replacement of mitral valve with MITRIS RESLIA Mitral Valve
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from valve related death or valve related reinterventionTime frame: 1 year
- Hemodynamic performance as measured by peak and mean gradient by echocardiographyTime frame: 1 year
Locations
34 sites in 4 countries. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Stanford University
Palo Alto, California
AdventHealth Orlando
Orlando, Florida
31 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.